1.Advances in immunosuppressive receptor LILRB4 in tumors and inflammatory diseases
Jingyi CHEN ; Yiliu LIU ; RUKEYA·Tu'erxunjiang ; Rui DING ; Jinping YIN ; Zuowen LIANG ; Jia ZHAO ; Jing LI
Chinese Journal of Immunology 2024;40(7):1559-1564
The leukocyte immunoglobulin-like receptor LILRB4(ILT3 or CD85k),a member of the immunosuppressive re-ceptor family,is expressed predominantly on the cell membranes of immune cells of myeloid origin,and exerts an immunosuppressive effect in immune regulation by activating either the autoinhibitory motif(ITIM)or by inhibiting Fc receptor activation motif(ITAM).In tumors,activation of LILRB4 receptor generates an immunosuppressive tumor microenvironment that assists in tumor invasion and metastasis,and in inflammatory diseases,LILRB4 is expressed on a variety of cells,such as monocytes,macrophages,mast cells,etc.,and attenuates inflammatory responses.Currently,LILRB4 has become a therapeutic target for tumors and various inflammatory diseases,and anti-LILRB4 monoclonal antibodies against acute myeloid leukemia(AML)have entered clinical trials.This review dis-cusses LILRB4 in terms of its structural distribution,signaling,therapeutic targets,and new drug development.
Result Analysis
Print
Save
E-mail